Skip to main content
Clinical Trials/JPRN-UMIN000050222
JPRN-UMIN000050222
Recruiting
未知

Clinical efficacy and predictors of effectiveness to anti-TSLP antibody (tezepelumab) in patients with asthma - Clinical efficacy and predictors of effectiveness to anti-TSLP antibody (tezepelumab) in patients with asthma

agoya City University0 sites36 target enrollmentFebruary 3, 2023

Overview

Phase
未知
Intervention
Not specified
Conditions
Asthma, Cough predominant asthma
Sponsor
agoya City University
Enrollment
36
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 3, 2023
End Date
February 2, 2029
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
agoya City University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with other obvious respiratory complications such as lung cancer, interstitial lung disease, etc. 2\) Pregnant or lactating patients. 3\) Patients who are judged to be inappropriate as subjects by the principal investigator.

Outcomes

Primary Outcomes

Not specified

Similar Trials